NEW YORK, March 27 (Reuters) - Johnson & Johnson will get a new chance to contest the scientific evidence linking talc products to ovarian cancer, a federal judge ruled on Wednesday, potentially disrupting a federal court case that consolidates 53,000 lawsuits. (Reporting by Dietrich Knauth; Editing by Leslie Adler)
Eli Lilly may be on the verge of another breakthrough, thanks to its hit GLP-1 medications.
The risk at these companies is above average, and they're sure to remain volatile. This volatility, however, includes explosively bullish potential.
The FDA approved Pfizer's hemophilia gene therapy on Friday. But Pfizer stock only inched ahead on the approval early Friday.
ResMed stock jumped Friday after crushing sales estimates and wiping out worries that weight-loss drugs would squeeze sleep apnea device sales.
Merck (MRK), Sanofi (SNY), Novartis (NVS) and AstraZeneca (AZN) announce their first-quarter results.
SNY earnings call for the period ending March 31, 2024.
The U.S. birth rate from 2023 was down 2% from 2022, according to the Centers for Disease Control and Prevention.
With the US obesity rate hovering at around 40%, tens of millions of Americans could take GLP-1 drugs over the next few years.
Gilead (GILD) reports narrower-than-expected loss in the first quarter. Its sales beat estimates on higher HIV, Oncology and Liver Disease sales.
Long-term care in residential facilities like nursing homes is a financial challenge for many. When dealing with a loved one who is disabled, elderly or ill, families often try every other kind of long-term care facility first. Because nursing homes … Continue reading → The post Nursing Home Costs: How You Can Cover Them appeared first on SmartAsset Blog.